Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics.
复制标题
肺动脉高压的药理治疗：探索药物基因组学。
DOI：
10.2217/fca.13.6
复制
发表时间：
2013-05
影响因子：
1.7
通讯作者：
Machado RF
中科院分区：
文献类型：
--
作者：
Duarte JD;Hanson RL;Machado RF
肺动脉高压(PH)是一种多种病因的疾病，分为五大类。在这些组中，对肺动脉高压(PAH)的研究最多，因此，目前所有可用的药物类别(前列环素类似物、内皮素受体拮抗剂和磷酸二酯酶5抑制剂)都被开发用于治疗PAH。因此，对于研究较少的非PAH形式的PH，存在有限的治疗数据。药物基因组学可以作为一种工具，更好地了解PH所涉及的途径，以及改善个体化治疗。然而，针对这种疾病的药物基因组学研究很少。来自重新调整用途的现有药物和新的治疗方法，治疗PH的新方法即将出现。
Pulmonary hypertension (PH) is a disease with multiple etiologies and is categorized into five broad groups. Of these groups, pulmonary arterial hypertension (PAH) is the most studied and, therefore, all of the currently available drug classes (prostacyclin analogs, endothelin receptor antagonists and phosphodiesterase type 5 inhibitors) were developed to treat PAH. Thus, limited treatment data exist for the less-studied non-PAH forms of PH. Pharmacogenomics can be a tool to better understand the pathways involved in PH, as well as to improve personalization of therapy. However, little pharmacogenomic research has been carried out on this disease. New treatments for PH are on the horizon, deriving from both repurposed currently available drugs and novel therapeutics.